
|Videos|March 7, 2022
Neurotech platform delivers biological agent over extended period to slow progression of retinal-based diseases
Author(s)Sheryl Stevenson
Rich Small, CEO of Neurotech, provides updates on the company’s pipeline that is the culmination of nearly 2 decades of research.
Advertisement
Rich Small, CEO of Neurotech, provides updates on the company’s pipeline that is the culmination of nearly 2 decades of research with Sheryl Stevenson, Ophthalmology Times®’ Group Editorial Director, during the New Horizons Forum at the 2022 Glaucoma 360 meeting
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
Retina Society 2026: MCO-010 optogenetic therapy maintains visual acuity gains through 4 years in advanced RP
2
DAYBREAK: Tarcocimab, tabirafusp-ted noninferior to aflibercept in wet AMD
3
Retina Society 2026: Could statins reduce PVR risk after RD repair?
4
Retina Society 2026: Medium-dose OCU410 gene therapy cuts geographic atrophy progression by up to 32% in phase 2 trial
5












